<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>生物制药小编 | wechat-feeds</title><link>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</link><description>“新起点，再出发”——生物医药小编与您共同关注生物制药行业热点。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 10 May 2021 10:17:54 +0800</pubDate><image><url>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</url><title>生物制药小编 | wechat-feeds</title><link>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>产能升级 | 康日百奥下游纯化生产线扩产</title><link>https://mp.weixin.qq.com/s/VsIZYUJlgodr3xjErxcK-w</link><description></description><content:encoded><![CDATA[产能升级 | 康日百奥下游纯化生产线扩产]]></content:encoded><pubDate>Sun, 09 May 2021 20:18:58 +0800</pubDate></item><item><title>国内Th17通路研发格局</title><link>https://mp.weixin.qq.com/s/h7d3P281EQlDCBToxsk3Pw</link><description></description><content:encoded><![CDATA[国内Th17通路研发格局]]></content:encoded><pubDate>Sun, 09 May 2021 20:18:58 +0800</pubDate></item><item><title>报名倒计时丨第二届生物药质量科学大会</title><link>https://mp.weixin.qq.com/s/vmfP5MdfT1DMWDXK4aiEoA</link><description></description><content:encoded><![CDATA[报名倒计时丨第二届生物药质量科学大会]]></content:encoded><pubDate>Sun, 09 May 2021 20:18:58 +0800</pubDate></item><item><title>10亿剂mRNA新冠疫苗年产能：复星医药/BioNtech在中国设立合资公司</title><link>https://mp.weixin.qq.com/s/oEXaDwVoiW-aKc6Has9qUw</link><description></description><content:encoded><![CDATA[10亿剂mRNA新冠疫苗年产能：复星医药/BioNtech在中国设立合资公司]]></content:encoded><pubDate>Sun, 09 May 2021 19:28:05 +0800</pubDate></item><item><title>健信生物完成：Claudin 18.2双抗、LAG-3双抗、TIM-3双抗、SIRPα双抗</title><link>https://mp.weixin.qq.com/s/2eFmXt9_rC67QuDsYeurdA</link><description></description><content:encoded><![CDATA[健信生物完成：Claudin 18.2双抗、LAG-3双抗、TIM-3双抗、SIRPα双抗]]></content:encoded><pubDate>Sat, 08 May 2021 13:35:19 +0800</pubDate></item><item><title>恒瑞医药第四款ADC启动临床研究</title><link>https://mp.weixin.qq.com/s/UbIsRFsD25Iv2t1Q3REXSg</link><description></description><content:encoded><![CDATA[恒瑞医药第四款ADC启动临床研究]]></content:encoded><pubDate>Sat, 08 May 2021 13:35:19 +0800</pubDate></item><item><title>ADC药物关键质量属性的考量因素</title><link>https://mp.weixin.qq.com/s/aTnsEQs603zlsTe_Zsv1lg</link><description></description><content:encoded><![CDATA[ADC药物关键质量属性的考量因素]]></content:encoded><pubDate>Thu, 06 May 2021 19:22:26 +0800</pubDate></item><item><title>单细胞蛋白组学技术正在成为CAR-T研发的主流</title><link>https://mp.weixin.qq.com/s/MPwDs7Yab2WK4hvt33QAMg</link><description></description><content:encoded><![CDATA[单细胞蛋白组学技术正在成为CAR-T研发的主流]]></content:encoded><pubDate>Thu, 06 May 2021 19:22:26 +0800</pubDate></item><item><title>细胞株开发整体解决方案</title><link>https://mp.weixin.qq.com/s/JRheIMdsxJ-DEaKbeYxomg</link><description></description><content:encoded><![CDATA[细胞株开发整体解决方案]]></content:encoded><pubDate>Wed, 05 May 2021 19:07:40 +0800</pubDate></item><item><title>内卷的Claudin 18.2</title><link>https://mp.weixin.qq.com/s/EiXjgo-Erpb_x8LDgo_RWg</link><description></description><content:encoded><![CDATA[内卷的Claudin 18.2]]></content:encoded><pubDate>Wed, 05 May 2021 19:07:40 +0800</pubDate></item><item><title>助力新一代“抗癌利器”—溶瘤病毒研发，CDE重磅发布全生命周期药学研究策略</title><link>https://mp.weixin.qq.com/s/eYp-IZl6nHHugsps8NjRJA</link><description></description><content:encoded><![CDATA[助力新一代“抗癌利器”—溶瘤病毒研发，CDE重磅发布全生命周期药学研究策略]]></content:encoded><pubDate>Tue, 04 May 2021 20:17:41 +0800</pubDate></item><item><title>如何让“质量问题”不再是质量部一个部门的事？</title><link>https://mp.weixin.qq.com/s/f7U2FS6zF53orWDsYZVksQ</link><description></description><content:encoded><![CDATA[如何让“质量问题”不再是质量部一个部门的事？]]></content:encoded><pubDate>Tue, 04 May 2021 20:17:41 +0800</pubDate></item><item><title>全新双靶点CAR-T：靶向肿瘤糖蛋白TAG-72和CD47</title><link>https://mp.weixin.qq.com/s/ZLhUA5NSwlrjcE9yhAx3Zg</link><description></description><content:encoded><![CDATA[全新双靶点CAR-T：靶向肿瘤糖蛋白TAG-72和CD47]]></content:encoded><pubDate>Mon, 03 May 2021 21:12:44 +0800</pubDate></item><item><title>如何让“质量问题”不再是质量部一个部门的事？</title><link>https://mp.weixin.qq.com/s/ESP6MNGzw2EoPLP-buPz-w</link><description></description><content:encoded><![CDATA[如何让“质量问题”不再是质量部一个部门的事？]]></content:encoded><pubDate>Mon, 03 May 2021 21:12:44 +0800</pubDate></item><item><title>糖基化：肿瘤的基本特征，抗癌药物关键靶点群</title><link>https://mp.weixin.qq.com/s/wUdPfqZv5FyN72Pf9B3Oqw</link><description></description><content:encoded><![CDATA[糖基化：肿瘤的基本特征，抗癌药物关键靶点群]]></content:encoded><pubDate>Sun, 02 May 2021 21:52:02 +0800</pubDate></item><item><title>讨论：质量人员要不要懂工艺和技术？</title><link>https://mp.weixin.qq.com/s/Gslf7ApPrchw4e4czFt3uQ</link><description></description><content:encoded><![CDATA[讨论：质量人员要不要懂工艺和技术？]]></content:encoded><pubDate>Sun, 02 May 2021 21:52:02 +0800</pubDate></item><item><title>发布最新财报和5年战略规划，第一三共2025财年剑指1.6万亿日元</title><link>https://mp.weixin.qq.com/s/zIDwnFabtXMQwwNsbVOKKQ</link><description></description><content:encoded><![CDATA[发布最新财报和5年战略规划，第一三共2025财年剑指1.6万亿日元]]></content:encoded><pubDate>Sat, 01 May 2021 21:40:40 +0800</pubDate></item><item><title>【喜迎五一，欢乐开抢】生产与质量管理论坛 议程首度发布！</title><link>https://mp.weixin.qq.com/s/l8R8hCb_aj7k9Gc4BawObA</link><description></description><content:encoded><![CDATA[【喜迎五一，欢乐开抢】生产与质量管理论坛 议程首度发布！]]></content:encoded><pubDate>Sat, 01 May 2021 21:40:40 +0800</pubDate></item><item><title>Best-in-Class SIRPα抗体</title><link>https://mp.weixin.qq.com/s/TkKY7j7zKfhgu6KVZASVKw</link><description></description><content:encoded><![CDATA[Best-in-Class SIRPα抗体]]></content:encoded><pubDate>Fri, 30 Apr 2021 18:08:58 +0800</pubDate></item><item><title>专访 |天科雅TCR-T实现肿瘤慢病化：五大核心技术</title><link>https://mp.weixin.qq.com/s/eX8CcrYeY9E_f-0SFzDw2w</link><description></description><content:encoded><![CDATA[专访 |天科雅TCR-T实现肿瘤慢病化：五大核心技术]]></content:encoded><pubDate>Fri, 30 Apr 2021 18:08:58 +0800</pubDate></item></channel></rss>